Vall d'Hebron Hospital is conducting the phase 1 clinical trial 'SERONCO-1' to evaluate a new compound called AOP208 (previously LB-208) in patients. This drug uses an unexplored mechanism of action in oncology, being considered 'first-in-class'.
The main objective of this trial is to assess the safety and determine the recommended dose of AOP208 in patients with advanced solid tumors that do not respond to conventional treatments. Additionally, it aims to understand the efficacy of this compound in the treatment of tumor stem cells, a novel approach in the fight against cancer.
According to the hospital's announcement, the first patient in the world has already received this experimental treatment. Dr. Elena Garralda, head of the Solid Tumors Clinical Research Group and coordinator of the trial, highlighted the significance of this milestone and the hope it represents for patients with advanced cancer.
The inclusion of patients in this clinical trial is a crucial step in oncological research, as it allows testing new therapeutic approaches and opening new doors in cancer treatment. The results of 'SERONCO-1' will be fundamental in determining the viability and efficacy of AOP208 as a treatment against tumor stem cells.
